Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study
Open Access
- 15 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (12) , 1437-1444
- https://doi.org/10.1093/hmg/ddm094
Abstract
Animal and human studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PLA2G5 and PLA2G2A genes) contribute to atherogenesis. Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, but no mass assay for sPLA2-V is available. We previously reported that tagging single nucleotide polymorphism (tSNP) haplotypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels. Here, we use tSNPs of the sPLA2-V gene to investigate the association of PLA2G5 with CHD risk markers. Seven PLA2G5 tSNPs genotypes, explaining >92% of the locus genetic variability, were determined in 519 patients with Type II diabetes (in whom PLA2G2A tSNP data was available), and defined seven common haplotypes (frequencies >5%). PLA2G5 and PLA2G2A tSNPs showed linkage disequilibrium (LD). Compared to the common PLA2G5 haplotype, H1 (frequency 34.9%), haplotypes H2–7 were associated with overall higher plasma LDL ( P < 0.00004) and total cholesterol ( P < 0.00003) levels yet lower oxLDL/LDL ( P = 0.006) and sPLA2-IIA mass ( P = 0.04), probably reflecting LD with PLA2G2A . Intronic tSNP (rs11573248), unlikely itself to be functional, distinguished H1 from LDL-raising haplotypes and may mark a functional site. In conclusion, PLA2G5 tSNP haplotypes demonstrate an association with total and LDL cholesterol and oxLDL/LDL, not seen with PLA2G2A , thus confirming distinct functional roles for these two sPLA2s.Keywords
This publication has 39 references indexed in Scilit:
- Secretory phospholipase A2 enzymes in atherogenesisCurrent Opinion in Lipidology, 2005
- Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesisEuropean Journal of Clinical Investigation, 2002
- Phospholipase A2in Vascular DiseaseCirculation Research, 2001
- Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectorisThe American Journal of Cardiology, 2000
- Circulating Levels of Secretory Type II Phospholipase A 2 Predict Coronary Events in Patients with Coronary Artery DiseaseCirculation, 1999
- Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and GlycosaminoglycansJournal of Biological Chemistry, 1999
- Expression of Phospholipase A 2 Isoforms in Human Normal and Atherosclerotic Arterial WallArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Localization of Nonpancreatic Secretory Phospholipase A 2 in Normal and Atherosclerotic ArteriesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Binding of Human Phospholipase A2 Type II to ProteoglycansJournal of Biological Chemistry, 1996
- Low-Molecular-Weight, Calcium-Dependent Phospholipase A2Genes Are Linked and Map to Homologous Chromosome Regions in Mouse and HumanGenomics, 1996